63 results
DEFM14A
PRTK
Paratek Pharmaceuticals, Inc.
2 Aug 23
Proxy related to merger
5:03pm
in force mass termination;
hire or promote any employees, except for hiring consistent with the budget previously disclosed to Parent prior to the date
PREM14A
PRTK
Paratek Pharmaceuticals, Inc.
30 Jun 23
Preliminary proxy related to merger
9:16am
or take any actions in preparation to implement any reduction in force mass termination;
hire or promote any employees, except for hiring consistent
DEFA14A
PRTK
Paratek Pharmaceuticals, Inc.
7 Jun 23
Additional proxy soliciting materials
6:11am
or promote any employees, except for hiring consistent with the budget previously disclosed to Parent prior to the date of this Agreement, to fill open
8-K
EX-2.1
PRTK
Paratek Pharmaceuticals, Inc.
7 Jun 23
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings
6:07am
termination;
(vii) hire or promote any employees, except for hiring consistent with the budget previously disclosed to Parent prior to the date
424B5
eptsaqh
17 May 21
Prospectus supplement for primary offering
8:02am
8-K
EX-99.1
d36xb1 ag
24 Feb 21
Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
5:29pm